Literature DB >> 9837824

Intragenic telSMN mutations: frequency, distribution, evidence of a founder effect, and modification of the spinal muscular atrophy phenotype by cenSMN copy number.

D W Parsons1, P E McAndrew, S T Iannaccone, J R Mendell, A H Burghes, T W Prior.   

Abstract

The autosomal recessive neuromuscular disorder proximal spinal muscular atrophy (SMA) is caused by the loss or mutation of the survival motor neuron (SMN) gene, which exists in two nearly identical copies, telomeric SMN (telSMN) and centromeric SMN (cenSMN). Exon 7 of the telSMN gene is homozygously absent in approximately 95% of SMA patients, whereas loss of cenSMN does not cause SMA. We searched for other telSMN mutations among 23 SMA compound heterozygotes, using heteroduplex analysis. We identified telSMN mutations in 11 of these unrelated SMA-like individuals who carry a single copy of telSMN: these include two frameshift mutations (800ins11 and 542delGT) and three missense mutations (A2G, S262I, and T274I). The telSMN mutations identified to date cluster at the 3' end, in a region containing sites for SMN oligomerization and binding of Sm proteins. Interestingly, the novel A2G missense mutation occurs outside this conserved carboxy-terminal domain, closely upstream of an SIP1 (SMN-interacting protein 1) binding site. In three patients, the A2G mutation was found to be on the same allele as a rare polymorphism in the 5' UTR, providing evidence for a founder chromosome; Ag1-CA marker data also support evidence of an ancestral origin for the 800ins11 and 542delGT mutations. We note that telSMN missense mutations are associated with milder disease in our patients and that the severe type I SMA phenotype caused by frameshift mutations can be ameliorated by an increase in cenSMN gene copy number.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9837824      PMCID: PMC1377643          DOI: 10.1086/302160

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  55 in total

1.  Molecular diagnosis of non-deletion SMA patients using quantitative PCR of SMN exon 7.

Authors:  C F Rochette; L C Surh; P N Ray; P E McAndrew; T W Prior; A H Burghes; M Vanasse; L R Simard
Journal:  Neurogenetics       Date:  1997-09       Impact factor: 2.660

2.  Linkage analysis of spinal muscular atrophy.

Authors:  R J Daniels; N H Thomas; R N MacKinnon; T Lehner; J Ott; T J Flint; V Dubowitz; J Ignatius; M Donner; K Zerres
Journal:  Genomics       Date:  1992-02       Impact factor: 5.736

3.  Linkage study of chronic childhood-onset spinal muscular atrophy (SMA): confirmation of close linkage to D5S39 in French Canadian families.

Authors:  L R Simard; M Vanasse; C Rochette; K Morgan; B Lemieux; S B Melançon; D Labuda
Journal:  Genomics       Date:  1992-09       Impact factor: 5.736

4.  Side chain contributions to the stability of alpha-helical structure in peptides.

Authors:  P C Lyu; M I Liff; L A Marky; N R Kallenbach
Journal:  Science       Date:  1990-11-02       Impact factor: 47.728

5.  Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q.

Authors:  J Melki; S Abdelhak; P Sheth; M F Bachelot; P Burlet; A Marcadet; J Aicardi; A Barois; J P Carriere; M Fardeau
Journal:  Nature       Date:  1990-04-19       Impact factor: 49.962

6.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

7.  Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3.

Authors:  L M Brzustowicz; T Lehner; L H Castilla; G K Penchaszadeh; K C Wilhelmsen; R Daniels; K E Davies; M Leppert; F Ziter; D Wood
Journal:  Nature       Date:  1990-04-05       Impact factor: 49.962

8.  Large differences in the helix propensities of alanine and glycine.

Authors:  A Chakrabartty; J A Schellman; R L Baldwin
Journal:  Nature       Date:  1991-06-13       Impact factor: 49.962

9.  Molecular analysis of candidate genes on chromosome 5q13 in autosomal recessive spinal muscular atrophy: evidence of homozygous deletions of the SMN gene in unaffected individuals.

Authors:  E Hahnen; R Forkert; C Marke; S Rudnik-Schöneborn; J Schönling; K Zerres; B Wirth
Journal:  Hum Mol Genet       Date:  1995-10       Impact factor: 6.150

10.  Isolation and characterization of a full-length expressible cDNA for human hypoxanthine phosphoribosyl transferase.

Authors:  D J Jolly; H Okayama; P Berg; A C Esty; D Filpula; P Bohlen; G G Johnson; J E Shively; T Hunkapillar; T Friedmann
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

View more
  53 in total

1.  Clinical utility gene card for: proximal spinal muscular atrophy.

Authors:  Sabine Rudnik-Schöneborn; Thomas Eggermann; Wolfram Kress; Henny H Lemmink; Jan-Maarten Cobben; Klaus Zerres
Journal:  Eur J Hum Genet       Date:  2012-04-18       Impact factor: 4.246

Review 2.  Applicability of histone deacetylase inhibition for the treatment of spinal muscular atrophy.

Authors:  Sebastian Lunke; Assam El-Osta
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

Review 3.  Genetic approaches to the treatment of inherited neuromuscular diseases.

Authors:  Bhavya Ravi; Anthony Antonellis; Charlotte J Sumner; Andrew P Lieberman
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

4.  Target resequencing of neuromuscular disease-related genes using next-generation sequencing for patients with undiagnosed early-onset neuromuscular disorders.

Authors:  Yuri Kitamura; Eri Kondo; Mari Urano; Ryoko Aoki; Kayoko Saito
Journal:  J Hum Genet       Date:  2016-06-30       Impact factor: 3.172

5.  Muscles in a mouse model of spinal muscular atrophy show profound defects in neuromuscular development even in the absence of failure in neuromuscular transmission or loss of motor neurons.

Authors:  Young Il Lee; Michelle Mikesh; Ian Smith; Mendell Rimer; Wesley Thompson
Journal:  Dev Biol       Date:  2011-05-30       Impact factor: 3.582

6.  Clinical utility gene card for: Proximal spinal muscular atrophy (SMA) - update 2015.

Authors:  Sabine Rudnik-Schöneborn; Thomas Eggermann; Wolfram Kress; Henny H Lemmink; Jan-Maarten Cobben; Klaus Zerres
Journal:  Eur J Hum Genet       Date:  2015-05-20       Impact factor: 4.246

Review 7.  Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.

Authors:  Natalia N Singh; Brian M Lee; Christine J DiDonato; Ravindra N Singh
Journal:  Future Med Chem       Date:  2015-09-18       Impact factor: 3.808

8.  Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts.

Authors:  Leigh A Skordis; Matthew G Dunckley; Baigong Yue; Ian C Eperon; Francesco Muntoni
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

9.  Intragenic complementation of amino and carboxy terminal SMN missense mutations can rescue Smn null mice.

Authors:  Vicki L McGovern; Kaitlyn M Kray; W David Arnold; Sandra I Duque; Chitra C Iyer; Aurélie Massoni-Laporte; Eileen Workman; Aalapi Patel; Daniel J Battle; Arthur H M Burghes
Journal:  Hum Mol Genet       Date:  2020-11-01       Impact factor: 6.150

10.  Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene.

Authors:  Laura Alías; Sara Bernal; Pablo Fuentes-Prior; María Jesus Barceló; Eva Also; Rebeca Martínez-Hernández; Francisco J Rodríguez-Alvarez; Yolanda Martín; Elena Aller; Elena Grau; Ana Peciña; Guillermo Antiñolo; Enrique Galán; Alberto L Rosa; Miguel Fernández-Burriel; Salud Borrego; José M Millán; Concepción Hernández-Chico; Montserrat Baiget; Eduardo F Tizzano
Journal:  Hum Genet       Date:  2008-12-03       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.